International review of cell and molecular biology最新文献

{"title":"Circadian rhythms and cardiac physiology: An essential interplay.","authors":"Rosanna Caputo, Alessandra Idini, Carolina Magdalen Greco","doi":"10.1016/bs.ircmb.2024.07.001","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2024.07.001","url":null,"abstract":"<p><p>Virtually every cell in the human body contains a molecular circadian clock that orchestrates the rhythmic oscillations of a multitude of tissue-specific functions. This is evident in the heart, where circadian rhythms are seen in various cardiac functions. Genetic disruption of clock genes has underscored their significance in regulating multiple aspects of cardiac physiology. In this review, we report the principal findings regarding the impact of clock gene manipulation (whole body or cardiomyocyte specific) on cardiac function. Furthermore, we present the current knowledge on the circadian clock in the different cell populations in the heart-cardiomyocytes, endothelial cells, fibroblasts, and immune cells. While increasing studies have shown mechanistic links between core clock components and cardiomyocytes-specific genes, the information of clock function within other cardiac cells in the heart is extremely limited. This review underlines the need to gain more information on the temporal segregation of clock processes in cardiac-especially in non-cardiomyocytes-cells, as clock-controlled mechanism may be target of chronotherapy to optimize current treatments for cardiovascular diseases.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"393 ","pages":"15-44"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulation tumor cell isolation and enrichment technologies.","authors":"Youbin Zhang, David Scholten, Wenan Qiang, Leonidas C Platanias, William J Gradishar, Shana O Kelley, Huiping Liu","doi":"10.1016/bs.ircmb.2025.01.009","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2025.01.009","url":null,"abstract":"<p><p>During cancer metastasis, tumor cells migrate from the primary tumor site and spread to distant tissue or organs through the circulatory system of the body. While it is challenging to track metastatic tumor cells, circulating tumor cells (CTCs) via liquid biopsy provide a unique and important opportunity for longitudinal monitoring of residual cancer diseases and progression, showing great potential to facilitate precision medicine in cancer patients. The enumeration and characterization of CTCs represent prognostic and predictive biomarkers, which can be used to monitor the response to and efficacy of various therapies. Along with molecular and cellular features of CTCs, this data can inform the detection of early micro-metastases and assess progression of advanced disease in a more sensitive manner than traditional imaging modalities, serving as a complementary approach with added value. Nevertheless, comprehensive multiomic analyses of CTCs at inter-cellular (cluster), single-cell, and subcellular levels to elucidate relevant CTC cancer biology, tumor immune ecosystem biology, and clinical outcomes have yet to be achieved, demanding multidisciplinary collaboration to advance the field. Complementary to the published chapter on multiomic analyses and functional properties of CTCs, this chapter summarizes key methods and integrated strategies in CTC isolation, highlighting an accelerated evolution in high-throughput analysis of CTCs.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"392 ","pages":"119-149"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiome and tumor immunotherapy.","authors":"Mohini Vig, Shweta Dubey","doi":"10.1016/bs.ircmb.2024.12.014","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2024.12.014","url":null,"abstract":"<p><p>Multiple innovative molecular techniques have established compelling connections between the gut microbiome and cancers. Studies have also revealed that the microbiome and microbiome-specific metabolites can significantly influence cancer treatments like chemotherapy, radiotherapy, and immunotherapy. Advancements in cancer immunotherapy driven by a targeted immune system approach have considerably improved the treatment landscape in cancer. However, the full potential of tumor immunotherapy remains to be explored, and many challenges need to be addressed. This review provides a summary of the current evidence regarding the presence of microbiota and how it can impact the response to Food and Drug Administration (FDA) approved cancer immunotherapies, such as immune checkpoint inhibitors (ICIs) or chimeric antigen receptor T (CAR-T) cell therapy. Additionally, it addresses the challenges and limitations of gut microbiome and cancer immunotherapy.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"394 ","pages":"147-170"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nectin-4: A promising prognostic marker and therapeutic target in cancer.","authors":"Shilpa Kuttikrishnan, Kirti S Prabhu, Ummu Habeeba, Zahwa Mariyam, Queenie Fernandes, Mohsin Maqbool, Omar M Khan, Ajaz A Bhat, Shahab Uddin","doi":"10.1016/bs.ircmb.2024.08.004","DOIUrl":"10.1016/bs.ircmb.2024.08.004","url":null,"abstract":"<p><p>Nectin cell adhesion protein 4 (Nectin-4), a calcium-independent immunoglobulin-like protein, has garnered significant attention in oncology due to its pronounced overexpression in malignant tumors and absence in healthy adult tissues. Elevated levels of Nectin-4 have been implicated in the pathogenesis of various cancers, including lung, breast, and urothelial carcinomas. Notably, Nectin-4 has emerged as a promising serological marker for these malignancies, facilitating early diagnosis and monitoring of disease progression. The clinical relevance of Nectin-4 is underscored by the Food and Drug Administration's approval of enfortumab vedotin (EV), the first antibody-drug conjugate targeting this protein, for the treatment of urothelial carcinoma. Ongoing clinical trials are expanding the therapeutic applications of EV, highlighting the critical role of Nectin-4 in targeted cancer therapy. Furthermore, novel therapeutic agents targeting Nectin-4 are under investigation, offering potential new avenues for cancer treatment. Despite these advancements, the precise molecular mechanisms by which Nectin-4 influences carcinogenesis and tumor progression remain inadequately understood. Challenges such as therapy-related adverse effects and the development of drug resistance further complicate the clinical management of Nectin-4-associated cancers. This review investigates the molecular functions of Nectin-4, emphasizing its diagnostic and prognostic value in cancer. We also explore the landscape of novel drug discoveries targeting Nectin-4 and provide an overview of current clinical trials aimed at utilizing this marker for therapeutic interventions. By elucidating the multifaceted role of Nectin-4 in malignancies, this article aims to advance our understanding and improve the clinical outcomes for patients with Nectin-4 overexpressing tumors.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"391 ","pages":"223-255"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding frontiers in liquid biopsy-discovery and validation of circulating biomarkers in renal cell carcinoma and bladder cancer.","authors":"Sabareeswaran Krishnan, Shruthi Kanthaje, Punchappady Devasya Rekha, M Mujeeburahiman, Chandrahas Koumar Ratnacaram","doi":"10.1016/bs.ircmb.2024.08.005","DOIUrl":"10.1016/bs.ircmb.2024.08.005","url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) and Bladder cancer (BC) are two lethal urological cancers that require diagnosis at their earliest stage causing decreasing survival rates in case of aggressive disease. However, there is no reliable circulating marker in blood or urine for their less or non-invasive diagnosis. Our objective was to review the potential circulating biomarkers, namely proteins, micro-RNA (miRNA), long non-coding RNA (lncRNA), and circulating tumour cells (CTCs) for which we performed a PubMed-based literature search of biomolecules (protein, miRNA, lncRNA and CTCs) found as circulating biomarkers in blood and urine for the early detection of RCC and BC. Among the numerous studies, certain biomolecules represent promising early-stage biomarkers such as proteins (NNMT, LCP1, and NM23A; KIM1), mi-RNAs (5-panel: miR-193a-3p, miR-362, miR-572, miR-378, and miR-28-5p; miR-200a) and lncRNAs (5-panel: LET, PVT1, PANDAR, PTENP1 and linc00963; GIHCG) for RCC. Similarly, proteins (APOA1), miRNAs (7-panel: miR-7-5p, miR-22-3p, miR-29a-3p, miR-126-5p, miR- 200a-3p, miR-375, and miR-423-5p; miRNA 181a, miRNA 30c, and miRNA 570) and lncRNAs (3-panel: MALAT1, MEG3, and SNHG16; exosomal derived 3-panel: PCAT-1, UBC1 and SNHG16; H19) were reported in BC subjects. Notably, the majority of the biomarkers presented for early detection in RCC cases were found in blood, while in urine for BC. Our results reveal that though a plethora of circulating biomarkers show early diagnostic ability, all of them are still bench-only biomarkers and require further validation. Adequate clinical trials/studies testing which of these potential markers individually or in combination, will become clinically applicable still remain elusive.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"391 ","pages":"135-197"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin 10: Bridging the chasms in the immune landscape of multiple myeloma.","authors":"Queenie Fernandes, Abdul W Ansari, Karama Makni-Maalej, Maysaloun Merhi, Said Dermime, Aamir Ahmad, Shahab Uddin","doi":"10.1016/bs.ircmb.2024.08.003","DOIUrl":"10.1016/bs.ircmb.2024.08.003","url":null,"abstract":"<p><p>Multiple myeloma (MM) is a complex hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow, leading to significant clinical challenges and a high burden of morbidity and mortality. Interleukin 10 (IL-10), a cytokine with potent anti-inflammatory properties, has emerged as a critical player in the pathobiology of MM. This work delves into the multifaceted role of IL-10 in MM, exploring its contributions to tumor growth, immune evasion, and drug resistance. Here, we examine IL-10's interactions with various immune cells within the bone marrow microenvironment and its potential as a circulatory biomarker for MM. Furthermore, we particularly lay emphasis on the prognostic and diagnostic implications of IL-10 levels in MM patients and evaluate the therapeutic prospects of targeting IL-10 in MM treatment regimens. By synthesizing current research, this review aims to enhance the understanding of IL-10 as a circulatory biomarker in MM and to highlight novel avenues for therapeutic intervention, thereby translating to improved clinical outcomes for MM patient.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"391 ","pages":"199-222"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity.","authors":"Irene Cánovas-Cervera, Elena Nacher-Sendra, Guillermo Suay, Agustin Lahoz, José Luis García-Giménez, Salvador Mena-Mollá","doi":"10.1016/bs.ircmb.2024.08.002","DOIUrl":"10.1016/bs.ircmb.2024.08.002","url":null,"abstract":"<p><p>The advent of immunotherapy in cancer has provided new avenues in the treatment of many malignancies at various stages. Specifically, immune checkpoint inhibitors (ICIs) have transformed the field of lung cancer treatment. However, since some tumors can evade the immune system, not all patients respond properly. Recent research has provided evidence showing how microRNAs (miRNAs) are involved in regulating many immune checkpoints. MiRNAs have demonstrated their ability to modulate immune evasion of tumor cells. Currently, reliable markers are being sought to predict the efficacy of immunotherapy in these types of cancers. Therefore, the association of serum miRNAs and the response of ICIs in lung cancer is under study. Many miRNA molecules and their corresponding target genes have been identified in the regulation of chemoresistance. Therefore, elucidating how these miRNAs control the function of immune checkpoints, as well as the effectiveness of therapies based on ICIs set the basis for the development of new biomarkers to predict treatment response to ICIs. This chapter delves into the molecular role of miRNAs interacting with ICs, such as PD-1 and PD-L1, and the clinical utility of miRNAs, such as miR-16, miR-146a, and miR-335, in predicting treatment response to ICI-based therapy in lung cancer. The aim is to provide a deep insight of the current landscape, serving as a cornerstone for further research.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"390 ","pages":"109-139"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of cell-free circulating epigenomic biomarkers for early diagnosis and response to therapies in breast cancer patients.","authors":"Pooja Ratre, Suresh Thareja, Pradyumna Kumar Mishra","doi":"10.1016/bs.ircmb.2024.10.003","DOIUrl":"10.1016/bs.ircmb.2024.10.003","url":null,"abstract":"<p><p>The increasing prevalence of breast cancer presents a significant global health challenge, highlighting the urgent need for improved diagnostic and treatment monitoring methods. The non-invasive nature of cell-free circulating epigenomic biomarkers, such as methylated DNA (metDNA) and microRNAs (miRNAs), offers a reassuring approach to identifying breast cancer patients in the early stages and assessing their response to therapy. This approach holds great promise for diagnosis and treatment evaluation, prioritizing patient comfort and well-being. Cell-free circulating metDNA and miRNAs are released into the bloodstream from dying tumor cells through apoptosis and necrosis, carrying tumor-specific genetic and epigenetic changes. These changes encompass alterations in DNA methylation patterns, are pivotal in regulating gene expression, and are frequently disrupted in cancer. The interplay between these processes and the dynamic release of epigenomic biomarkers provides a real-time snapshot of the genetic and epigenetic features of the tumor. Integrating the analysis of metDNA and miRNA biomarkers into clinical practice can facilitate the early detection of breast cancer and improve the precision of treatment monitoring. By tracking changes in these biological markers, healthcare professionals can make informed decisions regarding modifications to therapy, ultimately enhancing patient outcomes. Gaining insights into the underlying mechanisms of cell-free circulating epigenomic biomarkers offers a groundbreaking approach to diagnosing and treating breast cancer.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"391 ","pages":"95-134"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of microbiome in gastrointestinal cancer.","authors":"M P Sarath Krishnan, Bela Goyal, Leary Nampui, Subash Chandra Gupta","doi":"10.1016/bs.ircmb.2024.12.009","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2024.12.009","url":null,"abstract":"<p><p>The human microbiome consists of the diverse microorganisms with their equally diverse functional abilities that have evolved over millions of years with humans. This microbiome creates a mutually beneficial symbiotic relationship with their host. Through their varied functions, the human gut microbiota is crucial for preserving health and homeostasis. Any imbalance in this microbial population can lead to an array of diseased states, including cancer especially of the gastrointestinal system. The focus of this chapter is to discuss the mechanisms through which the gut microbiome creates a conducive environment for initiation and progression of cancer. In addition, the effect of microbial products such as short chain fatty acids, bile acids and Trimethylamine N-oxide on the formation of gastrointestinal cancer is also discussed. The various experimental methods and new molecular techniques that have facilitated the characterization and study of microorganisms is also discussed. The developments in microbiome research have shed light on the potential role of gut microbiota for novel biomarker discovery and therapeutic interventions in gastrointestinal cancer, like fecal microbiota transplantation. The prospects of these areas for further exploration are discussed.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"395 ","pages":"67-98"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144626348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine-driven cancer immune evasion mechanisms.","authors":"Enrique J Arenas","doi":"10.1016/bs.ircmb.2025.01.004","DOIUrl":"https://doi.org/10.1016/bs.ircmb.2025.01.004","url":null,"abstract":"<p><p>Cytokines play a dynamic crucial role in orchestrating homeostasis, immune responses, and the hallmarks and enabling characteristics of cancer cells, particularly by promoting tumor-inflammation and facilitating cancer immune evasion. By dysregulating cytokine production or hijacking signaling pathways, intrinsically or extrinsically, cancer cells can create an immunosuppressive tumor microenvironment that enables them to escape anti-tumor immune responses and promote survival, tumor growth, angiogenesis, metastasis and resistance to anticancer therapies, particularly immunotherapies. Despite extensive research, significant gaps remain in our understanding of cytokines, due to their pleiotropic and context-dependent nature, which varies based on cell type, tissue environment, and cytokine balance. While cytokines are typically classified as pro-inflammatory or immunosuppressive, most of them can act in both ways. Targeting cytokine signaling pathways holds substantial clinical potential, serving as prognostic and predictive biomarkers of response, and therapeutic targets that could improve anti-tumor outcomes, as demonstrated in various preclinical and clinical studies, either as monotherapy or in combination with anticancer therapies, including immunotherapies. For this reason, research focused on their understanding, particularly in how cytokines reshape the tumor microenvironment and the development of therapeutic strategies that target cytokine signaling has garnered increasing attention from the scientific community in recent years. In this review, we will describe the central role of cytokines in cancer, focusing on cytokine-driven mechanisms that contribute to the suppression of anti-tumor immune responses. We will uncover how cancer cells can exploit cytokine signaling pathways to dampen the immune response, promote tumor growth, facilitate metastasis, and enable resistance to anticancer therapies. Key cytokines, such as TGF-β, IL-10, LIF, VEGF, IFNγ, IL-2, IL-12, IL-1, IL-6, IL-8 and TNF-α will be described for their central role in cancer and immune evasion. Furthermore, we will discuss strategies aimed at targeting these cytokines signaling pathways as promising approaches that can improve anti-tumor immune responses and clinical outcomes, particularly in combination with cancer immunotherapies.</p>","PeriodicalId":14422,"journal":{"name":"International review of cell and molecular biology","volume":"396 ","pages":"1-54"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}